Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.
about
Hyaluronan (HA) interacting proteins RHAMM and hyaluronidase impact prostate cancer cell behavior and invadopodia formation in 3D HA-based hydrogelsiTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancerExpression of the Bcl-2 protein BAD promotes prostate cancer growthSox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cellsThe beta-catenin binding protein ICAT modulates androgen receptor activityHuman prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasterideCytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancerInterleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells.Androgen and retinoic acid interaction in LNCaP cells, effects on cell proliferation and expression of retinoic acid receptors and epidermal growth factor receptorChanges in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancerMolecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancerDeleted in liver cancer-1 (DLC1): an emerging metastasis suppressor geneTAF1 differentially enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin-activating and -conjugating domainsMultiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancerBeta-catenin phosphorylated at threonine 120 antagonizes generation of active beta-catenin by spatial localization in trans-Golgi networkIdentification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen.Oxidative stress, inflammation, and cancer: how are they linked?Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells.The lncRNA DRAIC/PCAT29 Locus Constitutes a Tumor-Suppressive Nexus.A metabolic perturbation by U0126 identifies a role for glutamine in resveratrol-induced cell death.Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP CellsCoevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis.Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.Can cancer cells transform normal host cells into malignant cells?Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model.Androgen-repressed phenotype in human prostate cancer.Supervillin reorganizes the actin cytoskeleton and increases invadopodial efficiency.Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacityBMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivoSIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas.Quantification of mineralized bone response to prostate cancer by noninvasive in vivo microCT and non-destructive ex vivo microCT and DXA in a mouse model.Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independenceMitochondria-mediated apoptosis by diallyl trisulfide in human prostate cancer cells is associated with generation of reactive oxygen species and regulated by Bax/BakHES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network.Novel tools for prostate cancer prognosis, diagnosis, and follow-upA networks method for ranking microRNA dysregulation in cancer.Gamma-glutamyltransferase activity in exosomes as a potential marker for prostate cancerThe von hippel-lindau protein suppresses androgen receptor activity.Advances in preclinical investigation of prostate cancer gene therapy.Bone marrow derived mesenchymal stem cells incorporate into the prostate during regrowth.
P2860
Q21090839-84C45938-8B34-40AD-B77D-5405EE10E991Q21134794-D762C23D-7B7C-40D5-8F38-EDB6ACCAFDE6Q24313520-28267A80-62E8-43B7-9049-442CD407EC8FQ24316490-5BBE2EA3-90CC-443B-966A-6DC400BD1E50Q24337124-ED3CB676-8ED2-4215-AE9D-2067A61773CFQ24603802-287928F3-A61A-4CB9-B65E-6FABB4C70EAEQ24654354-D554F124-A826-4B03-8816-BAB46213A2BEQ24746259-2D5DBD3A-6619-451B-905D-375B9E907B02Q24796211-143049EF-3AA5-4352-B290-BDEF2BCD3FC0Q24807354-A52271B4-C010-426C-8067-84A20C6A35A3Q26739708-01582CDA-8674-485E-99EC-9F801E89A385Q27025409-EDC84B6A-C847-4F4F-9930-5D09A914077FQ28119073-37394FA1-CB5C-4C2A-A2B7-41BBC01A275AQ28478514-D7D02BE5-8D39-4875-94C1-B123AF489D5AQ28482268-4BC8D133-9A8F-4578-83AA-40B685EC9C8EQ28727939-1115527F-BF41-4B8F-820A-460A41DAAC6BQ29616835-ACB173A4-CA78-40EB-B433-CC285E1D640DQ30276797-41737D08-04AB-4828-AE67-835417C07302Q30300669-1F3882B4-267A-4A3D-ADBD-8C715EFDBBC2Q30423585-F46AAD7E-CC82-413A-B118-9825B84F9284Q30431576-134637E7-EF6C-4898-BF92-54BC8CA8287DQ30432069-A0D3DCEB-F300-442A-A2B4-EC2489931780Q30435146-32F74050-1A6B-4807-9960-C0F888D7C2ECQ30438655-36B516BB-29C8-4476-807A-E9EB1E77E6AFQ30438661-8365F5E9-D752-4C31-8136-5026078FF59DQ30454285-D1FC0261-1B58-4422-AB17-BE49F2A4A9B7Q30485711-1E130910-D7C7-4A49-8B7A-4C135CE7DED9Q30853584-EF6EF841-DA24-434A-AA03-7055CFEF94D4Q33295288-D76D8570-CD92-4099-82DB-C6F62600C85AQ33302103-955BD62F-AB12-4080-9A34-E9A557B8FB4CQ33548724-216E15B1-B94E-44E0-9D5F-6E023E6082DBQ33579568-A085D7DD-E492-43F1-A539-DFA27040E567Q33587990-CD8EB66C-0CD3-421E-816D-0E0772F68F13Q33623369-51427D0D-743D-4ABA-93FE-7921CE8C7977Q33625338-BCF28909-853B-48AE-9D02-AB931C85AB69Q33641704-55C11FDD-F9FC-4131-8EB7-A1404A2847E8Q33644807-E1FAEC7D-93B5-4B96-AA62-1CBE05E1537CQ33669695-51FA8C7A-C521-43E7-80E0-8F5F53C47FB8Q33677054-B604C047-E5AB-4A13-B771-3B5FA5AB6DBCQ33707771-2BCBF626-2AE8-4B81-9421-7B13CE8937DF
P2860
Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.
description
1994 nî lūn-bûn
@nan
1994 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Androgen-independent cancer pr ...... odel of human prostate cancer.
@ast
Androgen-independent cancer pr ...... odel of human prostate cancer.
@en
Androgen-independent cancer pr ...... odel of human prostate cancer.
@nl
type
label
Androgen-independent cancer pr ...... odel of human prostate cancer.
@ast
Androgen-independent cancer pr ...... odel of human prostate cancer.
@en
Androgen-independent cancer pr ...... odel of human prostate cancer.
@nl
prefLabel
Androgen-independent cancer pr ...... odel of human prostate cancer.
@ast
Androgen-independent cancer pr ...... odel of human prostate cancer.
@en
Androgen-independent cancer pr ...... odel of human prostate cancer.
@nl
P2093
P4510
P1433
P1476
Androgen-independent cancer pr ...... odel of human prostate cancer.
@en
P2093
Anezinis PE
Hopwood VL
Thalmann GN
von Eschenbach AC
P304
P407
P577
1994-05-01T00:00:00Z